Zenas BioPharma, Inc. (ZBIO) · Nov 5, 2026 · Earnings
Mixed — EPS $(1.65) vs ~$1.24 consensus; revenue $10.0M vs ~$1.01M consensus
Zenas earnings show a $10 million collaboration milestone lifted revenue, while higher spending pushed EPS below consensus and left the core biotech story unchanged.
Zenas is moving from late-stage development toward a potential first commercial launch: obexelimab’s IgG4-RD application has been accepted by the FDA with a May 27, 2027 PDUFA date, while the company is preparing for a European filing and awaiting fourth-quarter SunStone SLE data. Its cash position was previously expected to support operations into 2029, assuming milestone and debt proceeds tied to approval.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenue (Income Statement) | $10.0M | $— | ~$1.01M |
| Net loss (Income Statement) | $(108.9M) | $(51.5M) | — |
| Diluted EPS (Income Statement) | $(1.65) | $(1.22) | ~$(1.24) |
| R&D expense (Income Statement) | $58.5M | $34.4M | — |
| Cash, equivalents and investments (Balance Sheet) | $647.1M | $360.5M | — |
The headline beat is largely accounting-driven, not commercial progress. Zenas recognized $10 million of license and collaboration revenue versus no revenue a year earlier, producing a large revenue beat against the roughly $1 million consensus. But this appears to be milestone-style collaboration revenue rather than product sales, so it does not yet validate commercial demand or change the company’s development-stage economics. The filing describes the business as still preparing for potential commercialization of obexelimab, not generating recurring product revenue. 〔0〕
Underlying spending accelerated as Zenas funds the transition toward commercialization. Research and development rose to $58.5 million from $34.4 million, general and administrative expense more than doubled to $27.4 million, and acquired in-process research and development reached $27.5 million. The result was a $108.9 million net loss, with diluted EPS of $(1.65), worse than the published consensus near $(1.24). The larger loss is not a new strategic setback, but it makes clear that the revenue beat did not offset the cost of advancing the pipeline and building commercial capabilities.
The meaningful near-term information remains clinical, not financial. Management kept the key fourth-quarter milestones in view: topline Phase 2 SunStone data in SLE and initial Phase 1 data for ZB021. 〔1〕 Those readouts, rather than this quarter’s one-time collaboration revenue, are what can materially change the business case. The filing does not introduce a new financing need or alter the previously established development path, although cash fell from $673.9 million at June 30 to $647.1 million at September 30.
Bottom line: This is a mixed quarter: a conspicuous revenue beat came from collaboration revenue, while operating losses exceeded expectations. It supports continued execution, but does not materially de-risk the core clinical and commercialization story.
SunStone SLE topline data and ZB021 Phase 1 data, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!